4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q1 EPS of ($1.01), $0.01 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $3.04 million versus the consensus estimate of $3.11 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.